中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (6): 514-520.doi: 10.19401/j.cnki.1007-3639.2016.06.006

• 论著 • 上一篇    下一篇

NRP1表达与晚期非小细胞肺癌一线含铂方案化疗敏感性及预后的相关性分析

冯卫能1,张良运2,石海燕2,陈泽程1,唐溢聪1,邓燕明1   

  1. 1. 佛山市第一人民医院头颈胸肿瘤内科,广东 佛山 528000 ;
    2. 佛山市第一人民医院病理科,广东 佛山 528000
  • 出版日期:2016-06-30 发布日期:2016-07-28
  • 通信作者: 邓燕明 E-mail: yanmingdeng78@126.com
  • 基金资助:
    广东省科技计划项目(20120318077);佛山市科技创新专项基金 (2014AG10003)。

NRP1 expression is associated with chemosensitivity and poor prognosis in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

FENG Weineng1, ZHANG Liangyun2, SHI Haiyan2, CHEN Zecheng1, TANG Yicong1, DENG Yanming1   

  1. 1.Department of Head, Neck and Thoracic Medical Oncology, the First People’s Hospital of Foshan, Foshan 528000, Guangdong Province, China; 2.Department of Pathology, the First People’s Hospital of Foshan, Foshan 528000, Guangdong Province, China
  • Published:2016-06-30 Online:2016-07-28
  • Contact: DENG Yanming E-mail: yanmingdeng78@126.com

摘要: 背景与目的:神经菌毛素-1(neuropilin-1,NRP1)作为血管内皮生长因子(vascular endothelial growth factor,VEGF)受体,在肿瘤新生血管形成和肿瘤细胞迁移中发挥重要作用。本研究目的是探索NRP1表达与晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)含铂一线化疗敏感性及预后的相关性。方法:应用免疫组织化学法检测104例一线应用含铂双药方案化疗的晚期NSCLC肿瘤组织中NRP1表达,采用χ2检验及Logistic回归模型分析NRP1表达与化疗反应率的关系。采用Kaplan-Meier和Cox比例风险回归模型分析NRP1表达对生存期的影响。结果:在104例患者中,56例(53.8%)出现NRP1高表达。NRP1高表达与年龄、性别、组织类型、分化程度、行为状态和化疗方案等临床病理因素无关。NRP1低表达患者的化疗反应率高于高表达患者(43.8% vs 23.2%,P=0.026)。Logistic多因素分析结果显示,NRP1表达为化疗反应率的独立预测因素(OR=3.103,95%CI:1.320~7.290,P=0.009),NRP1低表达患者较高表达患者具有更长的无进展生存期(4.6个月vs 3.0个月,χ2=11.273,P=0.001)和总生存期(11.5个月 vs 9.2个月,χ2=14.392,P=0.000),NRP1高表达是晚期NSCLC化疗反应率及总生存期的独立预测因素。结论:NRP1高表达与晚期NSCLC一线含铂联合化疗反应率和生存期相关,NRP1表达可能是预测晚期NSCLC化疗敏感性和预后的生物标志物。

关键词: 非小细胞肺癌, 神经菌毛素-1, 化疗敏感性, 预后

Abstract: Background and purpose: Neuropilin-1 (NRP1), a vascular endothelial growth factor (VEGF) receptor, plays an important role in tumor angiogenesis and tumor cell migration. The purpose of this study was to determine the correlation between NRP1 expression and sensitivity to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), and between NRP1 expression and survival. Methods: NRP1 expression in tumor tissues of 104 advanced NSCLC patients treated with first-line platinum-based regimen was detected by immunohistochemisty. A chi-square test and logistic regression model were used to analyze the relationship between NRP1 expression and the chemotherapy response rate. Kaplan-Meier and Cox proportional hazard regression models were used to analyze the effect of NRP1 expression on patient survival. Results: Among the 104 patients, 56 (53.8%) had high expression of NRP1. High expression of NRP1 was not related to age, gender, histological type, degree of differentiation, performance status, and chemotherapy regimen. The chemotherapy response rate was significantly higher in patients with low NRP1 expression than in patients with high expression (43.8% vs 23.2%, P=0.026). The low NRP1 expression was significantly associated with longer progression-free survival (4.6 months vs 3.0 months, P=0.001 for log-rank test, χ2=11.273) and overall survival (11.5 months vs 9.2 months, P=0.000 for log-rank test, χ2=14.392) as compared with high NRP1 expression. Multivariate analysis showed that high expression of NRP1 was an independent predictor for the chemotherapy response rate and overall survival in patients with advanced NSCLC. Conclusion: NRP1 expression is associated with response rate and survival in advanced NSCLC patients treated with first-line platinum-based chemotherapy. NRP1 expression may be a potential biomarker for predicting chemosensitivity and prognosis in patients with advanced NSCLC.

Key words: Non-small cell lung cancer, Neuropilin-1, Chemosensitivity, Prognosis